An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa
Article
Published on
Journal: Molecular therapy : the journal of the American So [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, 치료제,
Journal: Molecular therapy : the journal of the American So [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, 치료제,
[키워드] acute respiratory syndrome
adaptive
addition
anti-Spike IgG
B cells
Beta
boost
booster
cellular immunity
Central nervous system
Complete
coronavirus
coronavirus disease
COVID-19
COVID-19 vaccine
cross-protective
delta variant
effective
effector memory
Host
humoral
Humoral immunity
IgA
Immunity
immunization
induce
Infection
inflammatory properties
intranasal
intranasal vaccination
intranasally
lentiviral
lentiviral vaccine
lung
mice
mRNA
mucosa
mucosal
mucosal booster vaccine
mucosal immunity
nasal
non-replicative
omicron
organism
pandemic
Protective
reducing
SARS-CoV-2
SARS-CoV-2 emerging variants of concern
SARS-CoV-2 immunity
shown
specificity
susceptible
T cell
target
the SARS-CoV-2
transgenic mice
vaccination
vaccine candidate
variant
variants of concern
Viral transmission
waning anti-COVID-19 immunity.
[DOI] 10.1016/j.ymthe.2022.04.016 PMC 바로가기
[DOI] 10.1016/j.ymthe.2022.04.016 PMC 바로가기